SCHEMBL3351984

SCHEMBL3351984

CCCC(CCC)(CC(N)=O)C(N)=O

nearest known ligand 0.38

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FDPS P14324 4/20 0.38
LMNA P02545 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1032664 0.86 FDPS (0.42) FDPS
Valdipromide SCHEMBL2110001 0.85 LMNA (0.43) FDPSLMNAHSD17B10
SCHEMBL9218787 0.84 FDPS (0.37) FDPSLMNAHSD17B10
SCHEMBL7734575 0.83 FDPS (0.46) FDPS
SCHEMBL6564940 0.83 FDPS (0.46) FDPS
SCHEMBL7737126 0.83 FDPS (0.46) FDPS
SCHEMBL20510149 0.80 LMNA (0.40) FDPSLMNAHSD17B10
SCHEMBL4139680 0.80 ALDH1A1 (0.32) LMNAHSD17B10
SCHEMBL4658767 0.80 LMNA (0.40) FDPSLMNAHSD17B10
SCHEMBL3347762 0.79 FDPS (0.37) FDPSLMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117986145-A Synthesis method of bisamide derivative 中国石油化工股份有限公司 2024-05-07 CN disclosed
CN-107698437-A A kind of method for preparing the more formic acid analog derivatives of aromatic hydrocarbons 朱翠英 2018-02-16 CN disclosed
CN-107698438-A A kind of method for preparing the more formic acid analog derivatives of aromatic hydrocarbons 朱翠英 2018-02-16 CN disclosed
CN-107698436-A Method for preparing aromatic polycarboxylic acid derivative 朱翠英 2018-02-16 CN disclosed
CN-107698445-A A kind of method for preparing the more formic acid analog derivatives of aromatic hydrocarbons 朱翠英 2018-02-16 CN disclosed
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-7498436-B2 Substituted hydroxyethylamines PHARMACIA & UPJOHN COMPANY LLC (US) 2009-03-03 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-20070213407-A1 Compounds to treat Alzheimer's disease ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC 2007-09-13 US disclosed
US-7214715-B2 Compounds to treat Alzheimer's disease PHARMACIA & UPJOHN (US) 2007-05-08 US disclosed
US-20060106256-A1 Substituted hydroxyethylamines PHARMACIA & UPJOHN COMPANY 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213407-A1 Compounds to treat Alzheimer's disease PSEN2, PSEN1, CHAT FDPS 1260/4885LMNA 2675/4885HSD17B10 909/4885
US-20060106256-A1 Substituted hydroxyethylamines HNMT, PNMT, BCHE FDPS 2363/4885LMNA 1652/4885HSD17B10 767/4885
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP FDPS 1397/4885LMNA 479/4885HSD17B10 726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.